-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Neutral on Aardvark Therapeutics, Lowers Price Target to $2

Benzinga·10/26/2026 10:33:07
Diffusion vocale
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and lowers the price target from $4 to $2.